-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Primary type 1 hypergrassuria (PH1) is a rare genetic disease.
Recently, a research article was published in the top medical journal NEJM.
The primary endpoint of the study was the percentage change in urinary oxalic acid excretion from baseline to 6 months (average percentage change from 3 to 6 months).
A total of 39 patients in the study were randomized; 26 were assigned to the lumasiran group and 13 were assigned to the placebo group.
It can be seen that Lumasiran reduces the excretion of oxalic acid in the urine, which is the cause of progressive renal failure in patients with PH1.